← Back to headlines
Takeda's Psoriasis Drug Outperforms Bristol-Myers' Sotyktu in Late-Stage Study
A late-stage clinical study has shown that Takeda's psoriasis drug demonstrated superior performance compared to Bristol-Myers' Sotyktu, indicating a potential new treatment option for the condition.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
